|
Deuteranomaly
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We calculated CBD prevalences from allele-specific DNA sequences of 853 workers for Human Leukocyte Antigen (HLA)-DPB1 genotypes and groups characterized by number of E69-containing alleles and by calculated surface electronegativity of HLA-DPB1.
|
27414009 |
2016 |
|
Deuteranomaly
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multiple epidemiologic studies demonstrate associations between chronic beryllium disease (CBD), beryllium sensitization (BeS), and HLA-DPB1 alleles with a glutamic acid residue at position 69 (E69).
|
22972925 |
2012 |
|
Deuteranomaly
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because inbred strains of mice have not provided good models of CBD to date, three strains of HLA-DPB1 transgenic mice in an FVB/N background were developed; each contains a single allele of HLA-DPB1 that confers a different magnitude of risk for chronic beryllium disease: HLA-DPB1*0401 (OR approximately 0.2), HLA-DPB1*0201 (OR approximately 3), and HLA-DPB1*1701 (OR approximately 46).
|
19589099 |
2009 |
|
Deuteranomaly
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, both DRB1*13 and rs3117099TT homozygosity are associated with CBD in *Glu69-negative subjects, while DPB1*Glu69 is associated with CBD and BeS compared with Be-exp.
|
17927685 |
2007 |
|
Deuteranomaly
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although a glutamic acid in position 69 of the human leukocyte antigen-DP beta chain (HLA-DPB1-Glu69) is associated with the development of CBD, it cannot fully explain susceptibility.
|
15750822 |
2005 |
|
Deuteranomaly
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study identifies HLA-DP as a regulatory component in the activation of T cell receptors on Be-specific CD4+ T cells from CBD patients resulting in proliferation and proinflammatory cytokine production.
|
14975942 |
2004 |
|
Deuteranomaly
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Further, workers with CBD and sensitization were more likely to be homozygous HLA-DPB1(Glu69) compared to workers without disease or sensitization (P < 0.001).
|
15273960 |
2004 |
|
Deuteranomaly
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A higher frequency of the DPB1 Glu(69) gene was found in CBD and BeS compared with the Be-nondiseased subjects, with odds ratios of 10.1 for CBD vs Be-nondiseased and 9.5 for BeS vs Be-nondiseased.
|
14662898 |
2003 |
|
Deuteranomaly
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, HLA amino acid epitopes on HLA-DRB1 and -DQB1, in concert with or independently of HLA-DPB1-E69, may be associated with progression to CBD.
|
11897645 |
2002 |
|
Deuteranomaly
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This is the first direct evidence that HLA-DP genotype is linked to a phenotypic response that occurs in beryllium sensitization in the absence of clinical CBD.
|
11551429 |
2001 |
|
Deuteranomaly
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
One described Human Leukocyte Antigen gene variant, HLA-DP beta 1*0201, contains a substitution of glutamate for lysine at position 69 that appears to have high sensitivity (approximately 94%) but low specificity (approximately 70%) with respect to CBD among individuals occupationally exposed to respirable beryllium.
|
10795342 |
2000 |
|
Deuteranomaly
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Whereas most Glu69 carriers from the control group had a DPB1 allele *0201 (68%), most Glu69 carriers from the CBD group had a non-*0201 DPB1 Glu69-carrying allele (84%).
|
10415070 |
1999 |
|
Deuteranomaly
|
0.100 |
Biomarker
|
disease |
BEFREE |
This suggests that HLA-DP has a role in conferring susceptibility and that residue 69 of HLA-DPB1 could be used in risk assessment for CBD.
|
8105536 |
1993 |